Omega-3 Fatty Acids and Management of Cardiovascular Disease: What You Need to Know

Overview

This engaging, interactive presentation by 2 outstanding faculty will keep you up-to-date with topline recommendations from the excellent 2026 multi-society dyslipidemia guideline, the growing clinical trial evidence of omega-3 fatty acids in the management of cardiovascular disease, and strategies to improve adoption of guideline-recommended icosapent ethyl in clinical practice.

Learning Objectives

• Explain why therapy beyond statins is often needed to reduce overall ASCVD risk
• Discuss recent data of omega-3 fatty acids and how these findings are used in clinical practice scenarios to reduce ASCVD events
• Apply key recommendations from the 2026 Multi-society Guideline on the Management of Dyslipidemia